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Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by uncontrolled joint
inflammation and destruction of bone and cartilage. We previously reported that C-X-C motif chemokine 10
(CXCL10; also called IP-10) has important roles in joint inflammation and bone destruction in arthritis. However, the
specific mechanisms by which CXCL10 regulates the recruitment of inflammatory cells and the production of
osteoclastogenic cytokines in RA progression are not fully understood.
Methods: Bone marrow-derived macrophages and CD4+ T cells were isolated from wild-type (WT), Cxcl10–/–, and
Cxcr3–/– mice. CXCL10-induced migration was performed using a Boyden chamber, and CXCL10-stimulated production
of osteoclastogenic cytokines was measured by quantitative real-time PCR and ELISA. Collagen antibody-induced
arthritis (CAIA) was induced by administration of collagen type II antibodies and lipopolysaccharide to the mice. Clinical
scores were analyzed and hind paws were collected for high-resolution micro-CT, and histomorphometry. Serum was
used to assess bone turnover and levels of osteoclastogenic cytokines.
Results: CXCL10 increased the migration of inflammatory cells through C-X-C chemokine receptor 3 (CXCR3)-
mediated, but not toll-like receptor 4 (TLR4)-mediated, ERK activation. Interestingly, both receptors CXCR3 and TLR4
were simultaneously required for CXCL10-stimulated production of osteoclastogenic cytokines in CD4+ T cells.
Furthermore, calcineurin-dependent NFATc1 activation was essential for CXCL10-induced RANKL expression. In vivo,
F4/80+ macrophages and CD4+ T cells robustly infiltrated into synovium of WT mice with CAIA but were significantly
reduced in both Cxcl10–/– and Cxcr3–/– mice. Serum concentrations of osteoclastogenic cytokines and bone destruction
were also reduced in the knockout mice, leading to attenuated progression of arthritis.
Conclusion: These findings highlight the importance of CXCL10 signaling in the pathogenesis of RA and provide
previously unidentified details of the mechanisms by which CXCL10 promotes the development of arthritis.
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Background
Osteoclasts, multinucleated bone-resorbing cells, are
essential mediators of inflammatory bone erosion and
are derived from monocyte/macrophage lineage precur-
sor cells through the action of RANKL, a key factor for
osteoclastogenesis [1]. Increased bone resorption by acti-
vated osteoclasts can be caused by systemic alterations
such as the upregulation of osteotropic or osteoclastogenic
cytokines, including RANKL, TNFα, and IL-6, which in
turn cause bone-destructive diseases, including rheuma-
toid arthritis (RA) [2].
RA is a common, chronic inflammatory and systemic
autoimmune disease characterized by progressive infil-
tration of lymphocytes and macrophages into synovium,
leading to persistent synovial inflammation and destruc-
tion of bone and cartilage [3]. Abnormal activation of T
cells, one of the most abundant cell populations in the
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RA synovium, drives chronic inflammation and joint
destruction [4]. The T cells interact with other immune
and resident cells including macrophages by secreting
cytokines and chemokines or by direct cell-to-cell con-
tact, leading to a boost in production of proinflamma-
tory cytokines and chemokines [5, 6]. The increased
cytokines and chemokines in turn alter the activation or
differentiation state of one or both of the cell types [4].
In particular, elevated proinflammatory cytokines and
chemokines increase the expression of osteoclastogenic
cytokines including RANKL, TNFα, and IL-6 from CD4+
T cells of RA patients [7–9].
Synovitis, inflammation of a synovial membrane, is initi-
ated by infiltration of inflammatory cells into the synovial
compartment, followed by synovial hyperplasia, also called
pannus, in RA synovial tissue [3, 10]. The hyperplastic syn-
ovial pannus in RA produces proinflammatory cytokines,
chemokines, and proteases and subsequently invades and
destroys bone and cartilage [10, 11]. Particularly, macro-
phages and fibroblast-like synoviocytes are central effectors
of synovitis and synovial pannus formation, respect-
ively [3, 10]. Thus, infiltration of inflammatory cells
into the synovium is an essential step for the progres-
sion of RA.
C-X-C motif chemokine 10 (CXCL10), also known as
interferon-gamma-inducible protein 10 (IP-10), was ini-
tially identified as a chemokine secreted by several cell
types including macrophages, endothelial cells, and fi-
broblasts in response to interferon gamma (IFN-γ) [12].
CXCL10 binds to its receptor CXCR3 and regulates im-
mune responses through recruitment of leukocytes,
including T cells and monocytes/macrophages [12]. In
addition to its binding to CXCR3, CXCL10 has been
shown to bind with and activate toll-like receptor 4
(TLR4) [13]. The crucial role of CXCL10 has been well
characterized in chronic Th1 inflammatory diseases. In
inflamed tissues, CXCL10 recruits Th1 cells via CXCR3
where IFN-γ is secreted, which in turn stimulates
CXCL10 expression in various cell types, resulting in
positive feedback to amplify CXCL10 and Th1 responses
[14]. It has been shown that CXCL10 levels in synovial
fluid and serum are elevated in human RA patients and
in mice with collagen-induced arthritis (CIA) [6, 15, 16].
Blockade of the CXCL10–CXCR3 axis has been shown
to inhibit the infiltration of inflammatory cells, including
T cells and macrophages, into inflamed joints and to
decrease the severity of arthritis and bone and cartil-
age destruction in animal models of RA [6, 17]. In
addition to its chemotactic effect, CXCL10 has been
shown to increase RANKL expression in CD4+ T cells
[6, 18]. However, the exact mechanisms by which
CXCL10 regulates inflammatory cell infiltration and
osteoclastogenic cytokine production in RA are not
fully understood.
In general, the CIA model is widely used in animal
studies and shares many pathological and histological
similarities with RA, which is known to be both T-cell
and B-cell dependent. The model is commonly used to
evaluate both the antigen-recognition phase and the
inflammatory phase of arthritis [19]. However, the sus-
ceptibility for CIA is poor in mice of the C57BL/6 back-
ground, the strain widely used for knockout models. By
contrast, collagen antibody-induced arthritis (CAIA) is
induced by infiltration of neutrophils and macrophages
into the inflamed joints [20, 21]. Many of the patho-
logical symptoms that are typical of RA can be seen in
the joints of animals with CAIA, such as synovitis,
pannus formation, and destruction of cartilage and bone
[22, 23]. In addition, the CAIA model not only is a suit-
able model for studies of arthritis-induced osteoporosis
[24] but also can be used in genetically modified C57BL/
6 mice, such as transgenics and knockouts [22].
In this study, we investigated the functional roles
and specific mechanisms of CXCL10 signaling in RA




Wild-type (WT), Cxcl10–/–, and Cxcr3–/– mice (C57BL/
6 background) were obtained from The Jackson Labora-
tory (Bar Harbor, ME, USA). Tlr4–/– mice were kindly
provided by Dr Sung Joong Lee (Seoul National Univer-
sity, Seoul, Korea). All animal procedures were reviewed
and approved by the animal care committee of the Insti-
tute of Laboratory Animal Resources of Seoul National
University.
Induction and evaluation of CAIA
Male 8-week-old mice were injected intravenously with
a five-clone cocktail of collagen type II antibodies (5 mg/
mouse; Chondrex, Redmond, WA, USA) to induce arth-
ritis (CAIA group). Nonarthritic control mice received
phosphate-buffered saline (control group). Three days
after antibody administration, 100 μg lipopolysaccharide
(LPS) was injected intraperitoneally in both CAIA and
control mice.
The severity of arthritis was assessed according to
paw swelling and was scored on a scale of 0–3
(where 0 = normal, 1 = swelling of the toes, 2 = swell-
ing of the sole of the foot or increased swelling, and
3 = severe swelling or swelling of the entire paw). The
arthritic score for each mouse was expressed as the
sum of the scores of the four limbs. Mice were sacri-
ficed on day 12, and serum and paws were collected.
Paws were fixed in 4% paraformaldehyde overnight
and were then washed with PBS. Three-dimensional
images of posterior paws were obtained by microfocal
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computed tomography (micro-CT) scanning (SMX-90CT;
Shimadzu, Japan). An eroded bone surface per total bone
surface was determined using TRI 3D-BON software
(RATOC System Engineering Co., Kyoto, Japan). For
histological analysis, posterior paws were decalcified in
12% EDTA and then embedded in paraffin.
Histological evaluation
Paraffin-embedded sections of decalcified posterior paws
were prepared as described previously [25]. The sections
were stained with Harris hematoxylin and eosin (H&E),
Safranin O and methyl green staining, and tartrate-resistant
acid phosphatase (TRAP; Sigma-Aldrich, St Louis, MO,
USA) and then scored as described previously [26, 27].
The H&E-stained sections were scored for inflamma-
tion and pannus formation. Inflammation was scored ac-
cording to the following criteria: 0 = normal, 1 =minimal
infiltration, 2 =mild infiltration, 3 =moderate infiltra-
tion, 4 =marked infiltration, and 5 = severe infiltration.
Pannus formation was scored according to the following
criteria: 0 = no pannus formation, 1 =minimal pannus
formation, 2 =mild pannus formation, 3 =moderate
pannus formation, 4 = marked pannus formation, and
5 = severe pannus formation.
The Safranin O-stained sections were scored for cartil-
age damage. Cartilage damage was scored according to
the following criteria: 0 = no damage, 1 =minimal loss of
cartilage, 2 =mild loss of cartilage, 3 = moderate loss of
cartilage, 4 =marked loss of cartilage, and 5 = severe
diffuse loss of cartilage.
The TRAP-stained sections were scored for osteoclast
activity. Osteoclast activity was scored according to the
following criteria: 0 = no staining, 1 = rare positive cells,
2 = scattered staining, 3 =multiple foci of positive cells,
4 = clusters of positive cells, and 5 = diffuse staining.
Immunohistochemistry
Immunohistochemical analysis was performed on decal-
cified paraffin-embedded tissue sections as described
previously [28]. The anti-F4/80 antibody clone CI:A3-1
(Abcam, Cambridge, MA, USA) that recognizes the
mouse F4/80 antigen, a cell surface glycoprotein expressed
at high levels on various murine macrophages, was used
to detect macrophages in arthritic joints. Detection of the
primary antibody was performed using the VECTAS-
TAIN® Elite ABC kit (Vector Laboratories, Burlingame,
CA, USA), followed by 3,3-diaminobenzidine (Vector
Laboratories) incubation and nuclear staining with
hematoxylin. Six randomly chosen fields per slide were
analyzed and averaged.
Immunohistofluorescence
The deparaffinized sections were treated with a citrate
buffer (pH 6.0) for antigen retrieval in a microwave oven
for 30 min. After washing, tissue sections were blocked
for nonspecific binding with 5% horse serum/0.3%
Tween-20/TBS and incubated with FITC-labeled rat
anti-mouse CD4 (clone GK1.5, 1:100; eBioscience, San
Diego, CA, USA) antibody at 4 °C overnight. The FITC-
labeled rat igG2b K isotype control (clone eB149/10H5,
1:100; eBioscience) was used to control staining specifi-
city. After a final washing, cover slips were mounted
onto slides with fluoroshield mounting medium with
DAPI (four slips were mounted on indole; Abcam).
These sections were examined using an LSM 700
confocal laser-scanning microscope (Zeiss, Oberkochen,
Germany).
Isolation of bone marrow-derived macrophages and
activated CD4+ T cells and gene transduction
Bone marrow-derived macrophages (BMMs) were pre-
pared as described previously [25]. In brief, mouse bone
marrow cells were obtained from femurs and tibias and
incubated in α-MEM complete media containing 10%
fetal bovine serum, 100 units/ml penicillin, and 100 μg/
ml streptomycin on 10-cm culture dishes in the pres-
ence of M-CSF (10 ng/ml) overnight. Nonadherent cells
were transferred to 10-cm bacterial culture dishes and
were further cultured in the presence of M-CSF (30 ng/
ml) for 3 days. Adherent cells were used as BMMs after
the nonadherent cells were washed out.
CD4+ T cells were isolated from mouse spleens as
described previously [6]. Briefly, spleens were mashed in
Hanks’ balanced salt solution containing 3× antibiotics.
Cells were harvested, and red blood cells were removed
by ammonium–chloride–potassium (ACK) lysing buffer.
The remaining cells were collected and separated with a
Ficoll-Histopaque (Sigma-Aldrich) discontinuous gradi-
ent. The interface containing the cells was washed with
PBS, resuspended in RPMI 1640 (Welgene, Daegu,
Korea) containing 10% FBS, and then cultured for 1 day.
Nonadherent cells were then cultured for 3 days in the
presence of 50 ng/ml IL-2 (PeproTech, London, UK).
Activated CD4+ T cells were purified by negative
selection using CD4+ T-cell isolation kits (Miltenyi
Biotec, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions.
CD4+ T cells were transduced with the retroviral
vectors pMX-IRES-EGFP (control) or pMX-CA-NFATc1-
IRES-EGFP encoding a constitutively active (CA) form of
NFATc1 as described previously [25]. BMMs were trans-
duced with the adenoviral vectors Ax1w1 (control) or
AxMEKCA carrying CA-MEK1 (Ser 218 and Ser222 to
Glu) as described previously [29].
Migration assay
Amounts of 1 × 105 BMMs in 200 μl of serum-free α-
MEM were seeded in the upper well of a Boyden
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chamber with polycarbonate filters containing 8-μm
pore membranes (Corning Costar, Cambridge, MA,
USA). The lower well was loaded with 600 μl of serum-
free α-MEM with or without recombinant mouse
CXCL10 (PeproTech). After 12 hours of incubation, cells
attached on the lower surface of the membrane were
fixed with 100% methanol for 10 min and then stained
with Harris H&E. Migrated cells were quantified using
an image analysis system (Image J; National Institutes of
Health, Bethesda, MD, USA).
Amounts of 5 × 105 CD4+ T cells in 200 μl serum-free
RPMI 1640 medium were seeded in the upper well of
the Boyden chamber with polycarbonate filters contain-
ing 5-μm pore membranes. The lower well was loaded
with 600 μl serum-free RPMI 1640 medium with or
without recombinant mouse CXCL10 and the cells were
allowed to migrate for 12 hours. The migrated cells re-
covered from each bottom well were counted as follows:
100 μl of culture media containing migrated cells was
collected from each bottom chamber and counted as
migrated cells.
ELISA
The amount of CXCL10, RANKL, TNFα, IL-6, and C-
terminal telopeptides of type I collagen (CTX) in serum
was determined using the corresponding ELISA kits
(R&D Systems, Minneapolis, MN, USA) according to
the manufacturer’s instructions. In some experiments,
protein amounts of RANKL and TNFα in CD4+ T-cell
culture supernatants were determined using the same
ELISA kits mentioned earlier.
Immunoblotting
Immunoblot analysis was performed as described previ-
ously [25]. Specific antibodies against NFATc1 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), phospho-
ERK1/2 (Thr202/Tyr204) and ERK (Cell Signaling
Technology, Danvers, MA, USA), MEK1 (Millipore, Bos-
ton, MA, USA), and β-actin (Sigma-Aldrich) were used.
Reverse transcription and real-time PCR analysis
Total RNA was prepared from cells or spleens using an
RNeasy Mini kit (Qiagen, Valencia, CA, USA) according
to the manufacturer’s instructions, and cDNA was syn-
thesized from 2 μg of total RNA by reverse transcriptase
(Superscript II Preamplification System; Gibco-BRL,
Gaithersburg, MD, USA). Real-time PCR was performed
on an ABI Prism 7500 sequence detection system using
a SYBR® Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) and following the manufacturer’s
protocols. The ABI 7500 sequence detector was
programmed with the following PCR conditions: 40 cy-
cles of 15-s denaturation at 95 °C and 1-minute amplifi-
cation at 60 °C. All reactions were run in triplicate and
normalized to the housekeeping gene β-actin. The evalu-
ation of relative differences of PCR results was calculated
using the comparative cycle threshold (CT) method. The
following primer sets were used: mouse RANKL forward,
5′-TGGAAGGCTCATGGTTGGAT-3′ and reverse, 5′-
CATTGATGGTGAGGTGTGCA-3′; mouse TNFα for-
ward, 5′-GACCCTCACACTCAGATCATCTTCT-3′ and
reverse, 5′-CCTCCACTTGGTGGTTTGCT-3′; mouse IL-
6 forward, 5′-GTCCTTCCTACCCCAATTTCC A-3′ and
reverse, 5′-GGATGGTCTTGGTCCTTAGCC-3′; mouse
CXCR3 forward, 5′-CAGCCTGAACTTTGACAGAACC
T-3′ and reverse, 5′-GCAGCCCCAGCAAGAAGA-3′;
mouse TLR4 forward, 5′-AATCCTCTGGGGAGGCAC
AT-3′ and reverse, 5′-CAGGTCCAAGTTGCCGTTTC-
3′; and mouse β-actin forward, 5′-ATGTGGATCAGC
AAGCAGGA-3′ and reverse, 5′-AAGGGTGTAAAACGC
AGCTC-3′.
Statistical analysis
Data are presented as the mean ± SD (in-vitro data) or
the mean ± SEM (in-vivo data). Statistical analysis was
performed by either unpaired, two-tailed Student’s t test,
one-way ANOVA followed by Dunnett’s test, or two-way
repeated-measures ANOVA followed by Bonferroni’s test
using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA, USA). Values of P < 0.05 were considered
significant.
Results
CXCL10 induces migration of inflammatory cells through
CXCR3-mediated ERK activation but not TLR4
Because CXCL10 has been reported to bind to TLR4 as
well as to CXCR3 [13], we first investigated whether
TLR4 is involved in CXCL10-induced cell migration. We
isolated BMMs and CD4+ T cells from WT, Tlr4–/–, and
Cxcr3–/– mice. In our experimental condition, CD4+ T
cells from the WT, Tlr4–/–, and Cxcr3–/– spleens were
enriched to about 94% purity by magnetic bead separ-
ation (Additional file 1: Figure S1a), and IL-2 treatment
successfully increased CXCR3 and IL-2 mRNA expres-
sion with similar maintained viability of all CD4+ T cells
from WT, Tlr4–/–, and Cxcr3–/– mice (Additional file 1:
Figure S1b, c). We next carried out chemotactic assay
experiments. As expected, the CXCL10-induced migra-
tion of BMMs (Fig. 1a and Additional file 1: Figure S2)
and CD4+ T cells (Fig. 1b and Additional file 1: Figure
S3) was blocked in Cxcr3–/– or si-CXCR3 cells compared
with WT or si-Control cells. TLR4 knockout, however,
did not affect CXCL10-induced migration (Fig. 1a, b).
CXCL10 stimulates ERK [6], which positively regulates
cell migration [30]. Therefore, we checked whether
CXCL10 induces cell migration through the CXCR3–
ERK axis. ERK inhibition by PD98059, a specific MEK
inhibitor, greatly reduced CXCL10-induced migration of
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BMMs and CD4+ T cells (Fig. 1c and Additional file 1:
Figure S4). In addition, CXCR3 deficiency resulted in
failed CXCL10-induced ERK phosphorylation in both
BMMs and CD4+ T cells, whereas TLR4 deficiency did
not (Fig. 1d). The inhibition of CXCL10-induced ERK
phosphorylation and migration was largely rescued by
overexpression of a constitutively active MEK1 in
Cxcr3–/– cells (Fig. 1e, f ). These results suggest that
CXCR3-mediated ERK activation is crucial for the
CXCL10-induced cell migration.
Fig. 1 CXCL10 induces migration of BMMs and CD4+ T cells through CXCR3 but not TLR4. a, b BMMs and CD4+ T cells were isolated from
wild-type (WT), Tlr4–/–, and Cxcr3–/– mice and then the cells were serum starved. Cell migration in response to CXCL10 (100 ng/ml) was assessed
in transwell chambers for 12 hours. Representative images of migrated BMMs. (a, left panel; scale bar, 200 μm). Number of migrated BMMs (a,
right panel) and CD4+ T cells (b). c Serum-starved BMMs (left panel) and CD4+ T cells (right panel) were preincubated with DMSO or 10 μM
PD98059 for 1 hour, and migration was measured in the absence or presence of CXCL10 (100 ng/ml) after 12 hours. d Serum-starved BMMs (left
panel) and CD4+ T cells (right panel) were stimulated with CXCL10 (100 ng/ml) for the indicated times. Total cell lysates were immunoblotted with
the indicated antibodies. e, f WT or Cxcr3–/– BMMs were infected with adenovirus carrying empty vector (Ax1w1) or CA-MEK1 (AxMEKCA). After
24 hours, the infected cells were serum starved and stimulated with PBS (vehicle) or CXCL10 (100 ng/ml) for 5 min. Total cell lysates were
immunoblotted with the indicated antibodies (e). Migration of the infected cells in response to CXCL10 (100 ng/ml) was assessed in transwell
chambers for 12 hours. Representative images of migrated BMMs (f, left panel; scale bar, 200 μm) and the number of migrated BMMs (f, right
panel). Results shown are representative of three independent experiments (n = 3), and values are expressed as mean ± SD. *P < 0.001 by one-way
ANOVA followed by Dunnett’s test. CXCL10 C-X-C motif chemokine 10, Tlr4 toll-like receptor 4, Cxcr3 CXC chemokine receptor 3, n.s. nonsignificant,
BMM bone marrow-derived macrophage
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CXCL10 induces the production of osteoclastogenic
cytokines in CD4+ T cells through both TLR4 and CXCR3
Beyond its chemotactic effect, CXCL10 has been shown
to induce osteoclastogenic cytokines [6, 18]. Therefore,
we next investigated the functional role of CXCR3 and
TLR4 in response to CXCL10 in the expression of osteo-
clastogenic cytokines. Consistent with our previous
report [6], CXCL10 significantly induced RANKL, TNFα,
and IL-6 mRNA in CD4+ T cells isolated from WT mice,
but not in Cxcr3–/– CD4+ T cells (Fig. 2a). In line with
these results, the CXCL10-induced upregulation of
RANKL, TNFα, and IL-6 mRNA was greatly inhibited in
CXCR3-depleted CD4+ T cells (Additional file 1: Figure
S3). Interestingly, the inhibition was also found in CD4+
T cells isolated from Tlr4–/– mice (Fig. 2a). To confirm
this result, we measured the amount of RANKL, TNFα,
and IL-6 secreted into the culture medium by ELISA,
and the results were consistent with the mRNA expres-
sion (Fig. 2b). To exclude the possibility that the inhibi-
tory effect was a side effect of a genetic disorder, we
treated the CD4+ T cells with PMA/ionomycin to induce
RANKL expression [31]. As shown in Fig. 2c, PMA/
ionomycin-induced expression of both mRNA and pro-
tein for RANKL was not significantly different between
the cells. Altogether, these results suggest that both
CXCR3 and TLR4 are specifically required for CXCL10-
stimulated production of osteoclastogenic cytokines.
NFAT-binding sites exist in the RANKL promoter to
induce RANKL expression in CD4+ T cells, which is reg-
ulated by the calcineurin signaling pathway [31, 32].
Moreover, autoamplification of NFATc1 expression is
mediated by activated calcineurin-dependent NFATc1
activation [33, 34]. We reported previously that CXCL10
induces NFATc1 expression in CD4+ T cells [6], which
was abolished in both Cxcr3–/– and Tlr4–/– CD4+ T cells
(Fig. 2d). To investigate whether calcineurin signaling
plays a critical role in CXCL10-induced RANKL and
NFATc1 expression, we performed real-time PCR and
western blot analysis on samples prepared in the absence
or presence of cyclosporin A (CsA, an inhibitor of cal-
cineurin activity). Compared with the control, CsA pre-
treatment greatly inhibited CXCL10-induced RANKL
(Fig. 2e) and NFATc1 expression (Fig. 2f ). Furthermore,
overexpression of CA-NFATc1 fully rescued the failed
RANKL expression in both Cxcr3–/– and Tlr4–/– CD4+ T
cells (Fig. 2g, h). These data indicate that the calcineurin/
NFATc1 pathway is essential for CXCL10-induced
RANKL expression as well as NFATc1 expression in
T cells.
CAIA progression is ameliorated in Cxcl10–/– and Cxcr3–/–
mice
To determine the role of CXCL10 signaling in the devel-
opment of arthritis, we used the CAIA model in mice
lacking Cxcl10–/– and Cxcr3–/–. As shown in Fig. 3a, LPS
was used as a booster after injection of collagen type II
antibodies to induce severe arthritis in the CAIA model.
Because LPS is a specific ligand for TLR4, we excluded
Tlr4–/– mice in this study. In C57BL/6 WT mice, clinical
signs of arthritis were first observed 6 days after injection
of collagen type II antibodies and reached a maximum on
days 9–10. Cxcl10–/– and Cxcr3–/– mice developed less se-
vere arthritis than WT mice (Fig. 3b, c). Consistent with
the results of clinical scores, both Cxcl10–/– and Cxcr3–/–
mice had attenuated paw swelling compared with WT
mice (Fig. 3d). Next, we performed three-dimensional re-
construction and analysis of paws by micro-CT to check
bone erosion status. Micro-CT scans revealed erosive
bone lesions and an increase in eroded surface per total
bone surface following CAIA, which were significantly
decreased in Cxcl10–/– and Cxcr3–/– mice compared with
WT mice (Fig. 3e, f ).
To accurately evaluate the degree of inflammation,
pannus formation, and cartilage destruction, joint tissue
sections were examined using a histopathologic scoring
system [26, 27]. Histopathologic studies also revealed
milder inflammation, pannus formation, and cartilage
degeneration following CAIA in Cxcl10–/– and Cxcr3–/–
mice than in WT mice (Fig. 4a–d). In order to detect os-
teoclasts, we performed TRAP staining. In line with the
results of micro-CT analysis, lower osteoclast activity
was observed in Cxcl10–/– and Cxcr3–/– mice than in
WT mice (Fig. 4a–d).
Taken together, these results demonstrate that the
clinically observed amelioration of arthritis in Cxcl10–/–
and Cxcr3–/– mice was reflected by suppression of joint
inflammation and destruction of bone and cartilage.
Cxcl10–/– and Cxcr3–/– mice with CAIA have decreased
F4/80+ macrophages and CD4+ T-cell accumulation in
arthritic joints and serum concentrations of osteoclastogenic
cytokines
Next, we carried out immunohistochemistry with an
anti-F4/80 antibody and immunohistofluorescence with
an anti-CD4-FITC antibody to check the extent of F4/80+
macrophages and CD4+ T-cell infiltration into the syno-
vium, respectively. A significant reduction in both F4/80+
macrophages and CD4+ T-cell infiltration was observed in
Cxcl10–/– and Cxcr3–/– mice compared with WT mice
under the CAIA condition (Fig. 5a–d).
We have shown previously that CXCL10 levels are
markedly increased in the inflamed joints and serum of
CIA mice and that neutralization of CXCL10 by anti-
bodies decreases CIA-induced elevation of RANKL and
TNFα levels in serum [6]. Similar to the previous find-
ings, C57BL/6 WT mice with CAIA exhibited a signifi-
cant elevation of CXCL10, RANKL, TNFα, and IL-6
levels in serum compared with control mice. However,
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Fig. 2 (See legend on next page.)
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the CAIA-induced protein levels of RANKL, TNFα, and
IL-6 in serum were markedly suppressed in Cxcl10–/–
and Cxcr3–/– mice compared with their WT counter-
parts (Fig. 6a, b). In addition, CAIA greatly induced the
mRNA expression of CXCL10, RANKL, TNFα, and IL-6
in spleens from WT mice, but not in spleens from
Cxcl10–/– and Cxcr3–/– mice (Fig. 6c, d). Interestingly,
we also found that the elevated protein or mRNA ex-
pression of CXCL10 in serum or spleen from WT mice
with CAIA is abrogated in Cxcr3–/– mice (Fig. 6b, d),
suggesting that CXCR3 signaling may involve an amplifi-
cation of its ligand CXCL10 in the CAIA model.
Because CAIA-induced osteoclast activity was signifi-
cantly decreased in Cxcl10–/– and Cxcr3–/– mice (Fig. 4),
we measured serum CTX levels, a marker of bone re-
sorption. As shown in Fig. 6a, b, serum CTX levels were
increased by CAIA in WT mice, which was greatly
inhibited in Cxcl10–/– and Cxcr3–/– mice.
Discussion
CXCL10 has been found to be highly expressed in the
serum and synovial fluid of RA patients [15, 16]. Fur-
thermore, previous studies have shown that pharmaco-
logic blockade of CXCL10 signaling inhibits arthritis
progression in animal models, mainly via inhibition of
T-cell migration into the joint [6, 17, 35]. In the present
study with Cxcl10–/– and Cxcr3–/– mice, we showed that
the CXCL10–CXCR3 axis plays important roles in local
and systemic inflammation in a CAIA model.
Infiltration of inflammatory cells into synovium is a
crucial step in the progression of RA. The accumulation
of inflammatory cells in the synovium mainly reflects
migration rather than local proliferation [3]. CAIA is re-
ported to be induced by infiltration of neutrophils and
macrophages, which are the main effector cells in CAIA,
into the inflamed joints [20, 21, 36]. Al-Banna et al. [37]
showed that the accumulation of T cells in inflamed
lymph nodes is highly CXCR3 dependent and that
CXCR3 deficiency reduces the development of arthritis
in a CIA model. In addition, Mohan and Issekutz [17]
showed that blockade of CXCR3 inhibits T-cell and neu-
trophil recruitment to inflamed joints and decreases the
severity of adjuvant arthritis. In the present study, we
found that CXCL10 stimulates migration of BMMs and
CD4+ T cells through CXCR3-mediated ERK activation
(Fig. 1). We also found that Cxcl10–/– and Cxcr3–/– mice
showed less joint inflammation (Figs. 3 and 4) with re-
duced accumulation of F4/80+ macrophages and CD4+
T cells in the synovium (Fig. 5) compared with WT
mice. Taken together, these results suggest that the
CXCL10–CXCR3–ERK pathway may play a role in the
accumulation of inflammatory cells during the develop-
ment of arthritis.
It has been shown that inflammatory cytokine-
expressing CD4+ T cells in the spleen and RANKL-
expressing CD4+ T cells in blood are increased in the
CAIA model [38]. In addition, inflammatory cytokine
levels are systemically elevated in blood in CAIA mice
[39]. Consistent with these reports, the protein and
mRNA levels of RANKL, TNFα, IL-6, and CXCL10 in
serum or spleens were elevated in WT mice with CAIA;
however, elevation of these cytokines was abrogated in
Cxcl10–/– and Cxcr3–/– mice (Fig. 6). We also found that
CXCL10 stimulated the expression of RANKL, TNFα,
and IL-6 in CD4+ T cells in a CXCR3-dependent and
TLR4-dependent manner (Fig. 2a, b). Enhanced levels of
RANKL and TNFα play an essential role in inflamma-
tion and mediate cartilage and bone destruction in RA
[2, 40, 41]. CD4+ T cells are considered one of the major
sources of inflammatory cytokines, especially of soluble
RANKL, in arthritis. In fact, activated CD4+ T cells
expressing soluble RANKL have been shown to cause
severe joint inflammation and bone and cartilage de-
struction in adjuvant arthritis [42]. It is thus likely that
CXCL10 signaling contributes to CAIA-induced RANKL
production at least in part through CD4+ T cells in vivo.
Recently, Grahnemo et al. [24] showed that CAIA is as-
sociated with an increased number of osteoclasts and
(See figure on previous page.)
Fig. 2 CXCL10 stimulates production of osteoclastogenic cytokines in CD4+ T cells through TLR4 and CXCR3. a, b CD4+ T cells were isolated from
WT, Tlr4–/–, and Cxcr3–/– mice, and serum-starved CD4+ T cells were cultured with or without CXCL10 (100 ng/ml) for 24 hours. RANKL, TNFα, IL-6,
CXCR3, and TLR4 mRNA levels were analyzed by real-time PCR (a). RANKL, TNFα, and IL-6 protein levels in culture media were quantified by ELISA
(b). c CD4+ T cells from WT, Tlr4–/–, and Cxcr3–/– mice were serum starved and treated with or without 500 ng/ml ionomycin and 20 ng/ml PMA
(P/I) for 6 hours. RANKL mRNA levels and RANKL protein levels in culture media were measured by real-time PCR (left panel) and ELISA (right
panel), respectively. d CD4+ T cells were serum starved and treated with or without CXCL10 (100 ng/ml) for 24 hours. Total cell lysates were
immunoblotted with the indicated antibodies. e, f Serum-starved WT CD4+ T cells were preincubated with DMSO or 10 nM CsA and then
stimulated with or without CXCL10 (100 ng/ml) for 24 hours. RANKL mRNA levels were analyzed by real-time PCR (e). NFATc1 protein levels were
measured by western blotting (f). g, h CD4+ T cells from the indicated mice were transduced with the retroviral vectors pMX-IRES-EGFP (pMX) or
pMX-CA-NFATc1-IRES-EGFP (pMX-CA-NFATc1). The cells were serum starved and cultured with or without CXCL10 (100 ng/ml) for 24 hours. Total
cell lysates were immunoblotted with the indicated antibodies (g). RANKL mRNA levels (h, left panel) and RANKL protein levels in culture media
(h, right panel) were measured. Results shown are representative of three independent experiments (n = 3), and values are expressed as mean ± SD.
*P < 0.001 by one-way ANOVA followed by Dunnett’s test. CXCL10 C-X-C motif chemokine 10, RANKL receptor activator of nuclear factor kappa-B ligand,
TNFα tumor necrosis factor alpha, IL-6 interleukin 6, Tlr4 toll-like receptor 4, Cxcr3 CXC chemokine receptor 3, WT wild-type, NFATc1 nuclear factor of
activated T cells, cytoplasmic 1, DMSO dimethyl sulfoxide, CsA cyclosporin A, ND not detected, n.s. nonsignificant
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trabecular bone loss. In the present study, CAIA-
induced destruction of bone and cartilage in inflamed
joints (Figs. 3 and 4) and elevation of CTX levels in
serum (Fig. 6a, b) were significantly reduced in Cxcl10–/
– and Cxcr3–/– mice. Collectively, these findings suggest
that the elevation of CXCL10 signaling increases the
production of cytokines including RANKL, TNFα, and
IL-6, leading to destruction of bone and cartilage during
the development of CAIA.
The RANKL gene promoter region in CD4+ T cells
contains several recognition sequences for transcription
factors, including NFAT, c-Fos, and NF-κB [31]. Wang
et al. [32] have shown that intracellular calcineurin
signaling downstream of T-cell receptor activation is
critical for RANKL expression, which suggests that
calcineurin-dependent NFAT activation may be involved
in RANKL expression in CD4+ T cells. Activated calcine-
urin signaling can induce autoamplification of NFATc1
Fig. 3 Amelioration of CAIA development in Cxcl10–/– and Cxcr3–/– mice. a Experimental design of CAIA. WT, Cxcl10–/–, and Cxcr3–/– mice were
subjected to collagen type II antibodies + LPS (CAIA) or LPS injection (control). b–d Development of CAIA was monitored for 12 days, and
arthritic scores were assessed by the degree of swelling in each paw (scored 0–3). Arthritic scores in WT and Cxcl10–/– mice (b, n = 5 each) and
WT and Cxcr3–/– mice (c, n = 5 each) subjected to CAIA. Data represent mean ± SEM. *P < 0.01; **P < 0.001 vs WT at each time point by two-way
repeated-measures ANOVA followed by Bonferroni’s test. Representative photographs of CAIA-induced paw swelling on day 9 (d). e, f Representa-
tive micro-CT images and quantification of bone surface erosion in the hind paws from WT and Cxcl10–/– mice (e; n = 5 each group) and WT and
Cxcr3–/– mice (f, n = 5 each group) on day 12. Arrows indicate bone erosions. Data represent mean ± SEM. *P < 0.001 by one-way ANOVA followed
by Dunnett’s test. LPS lipopolysaccharide, WT wild-type, CXCL10 C-X-C motif chemokine 10, Cxcr3 CXC chemokine receptor 3, CAIA collagen
antibody-induced arthritis
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through NFATc1-dependent NFATc1 gene transcription
[33]. In the present study, we found that CXCL10 in-
creases NFATc1 and RANKL expression in CD4+ T cells
in a CXCR3-dependent and TLR4-dependent manner
(Fig. 2). Treatment of CD4+ T cells with CsA, an inhibi-
tor of calcineurin activity, suppressed CXCL10-induced
NFATc1 and RANKL expression. Moreover, the impair-
ment of CXCL10-induced RANKL expression in Cxcr3–/
– and Tlr4–/– CD4+ T cells was greatly rescued by over-
expression of CA-NFATc1 (Fig. 2g, h). Therefore, our
results indicate that CXCL10 induces RANKL expression
in CD4+ T cells via the activation of NFATc1 in a CXCR3-
dependent and TLR4-dependent manner. Although it has
been shown that TLR4 is involved in the pathophysiology
of RA in CIA and K/BxN serum transfer animal models
[43, 44], the functional role of TLR4 in CXCL10-mediated
production of cytokines contributing to destruction of
bone and cartilage during the development of RA remains
to be elucidated.
It is well known that CXCR3 is the main receptor for
CXCL10. In line with this fact, CXCL10-induced cell
migration and cytokine production were completely abol-
ished in BMMs and CD4+ T cells from Cxcr3–/– cells
(Figs. 1 and 2). Interestingly, however, we found that
CXCL10-induced cytokine production was also abolished
in Tlr4–/– CD4+ T cells even though the CXCR3 expression
Fig. 4 Histological analysis of arthritic lesions in Cxcl10–/– and Cxcr3–/– mice with CAIA. Tissue sections were obtained from paw joints of the same
mice as in Fig. 3 on day 12 after arthritic induction. Representative images of Safranin O, H&E, and TRAP staining (a, c) and quantification of
histological analysis (b, d) of joint tissue sections from WT and Cxcl10–/– mice (a, b) and WT and Cxcr3–/– mice (c, d) with CAIA. Fourth panel (a, c)
is a higher magnification image of the boxed area in the third panel. Scale bar, 400 μm (first–third panels) and 100 μm (fourth panel). Data
represent mean ± SEM of results in five samples of staining (n = 5). *P < 0.001 vs WT mice by unpaired Student’s t test. WT wild-type, CXCL10 C-X-C
motif chemokine 10, Cxcr3 CXC chemokine receptor 3, H&E hematoxylin and eosin, TRAP tartrate-resistant acid phosphatase (Color figure online)
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was intact in these cells (Fig. 2). These results suggest
that TLR4 is specifically required for CXCR3 signaling
in CXCL10-induced cytokine production, but not in
CXCL10-induced cell migration. It has been reported
that TLR4 activation induces an upregulation of
chemokine expression including CXCL10 [45]. Recently,
we have reported that CXCL10 induces CXCL10 expres-
sion through CXCR3 [46]. The TLR4 activation-induced
or CXCR3-mediated CXCL10 upregulation can exert im-
portant roles in arthritis progression through TLR4 and
CXCR3, suggesting that it could form a positive feedback
loop between CXCL10 and its receptors TLR4 and/or
CXCR3. In addition, several studies have shown crosstalk
between TLRs and GPCR signaling. Eskan et al. [47]
showed that TLR4 and S1P receptors coordinate to
enhance inflammatory cytokine production in epithelial
cells. GPCR agonist has been shown to transactivate TLRs
via mammalian neuraminidase-1 sialidase and matrix
metalloproteinase-9 crosstalk [48]. Moreover, TLR signal-
ing has been reported to regulate GPCR signals by altering
Fig. 5 Reduction of macrophages and CD4+ T cells accumulation in arthritic joints of Cxcl10–/– and Cxcr3–/– mice with CAIA. a, b Joint tissue
sections from WT, Cxcl10–/– (a), and Cxcr3–/– (b) mice with CAIA used in Fig. 4 were stained with an IgG or an anti-F4/80 antibody. Representative
images of F4/80 staining of joint tissue sections from each group (top panel) and quantification of F4/80-positive cells (bottom panel). IgG,
negative control. Scale bar, 200 μm. Data represent mean ± SEM of results in five samples (n = 5). *P < 0.001 vs WT mice by unpaired Student’s
t test. c, d Joint tissue sections from WT, Cxcl10–/– (c), and Cxcr3–/– (d) mice with CAIA used in Fig. 4 were stained with a control-FITC or an
anti-CD4-FITC antibody. Representative images of CD4-FITC staining of joint tissue sections from each group (second and third topmost panels)
and quantification of CD4-positive cells (bottom panel). Con-FITC, negative control. Scale bar, 20 μm. Data represent mean ± SEM of results in five
samples (n = 5). *P < 0.001 vs WT mice by unpaired Student’s t test. WT wild-type, CXCL10 C-X-C motif chemokine 10, Cxcr3 CXC chemokine
receptor 3, IgG immunoglobulin G, DAPI 4′,6-diamidino-2-phenylindole, FITC fluorescein isothiocyanate
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the expression of regulator of G protein signaling proteins
in inflammatory cells [49, 50]. However, analysis of how
TLR4 cooperates with CXCR3 in CXCL10-induced cyto-
kine production remains to be elucidated.
As mentioned earlier, several cells including macro-
phages, T cells, neutrophils, and fibroblast-like synovio-
cytes have been considered relevant components of RA
progression. These cells in the inflamed joint or other
organs have roles in secretion of proinflammatory cyto-
kines/chemokines, synovitis, and synovial pannus forma-
tion, leading to chronic inflammation and joint
destruction [3]. In the present study, we used global
Cxcl10–/– and Cxcr3–/– mice to investigate the patho-
genic roles of CXCL10 signaling in a CAIA model and
obtained less inflammation, accumulation of F4/80+
macrophages and CD4+ T cells, cytokine production, car-
tilage degeneration, and bone destruction in those mice.
Accumulating evidence has shown that neutrophil recruit-
ment in the joints is reduced by blockade of CXCR3 [17]
and that CXCL10/CXCR3 signaling regulates invasion of
fibroblast-like synoviocytes [51]. Given these reports, we
cannot rule out that defective CXCL10 signaling in those
cells including neutrophil and fibroblast-like synoviocytes
might contribute to the inhibitory results of arthritis pro-
gression seen in Cxcl10–/– and Cxcr3–/– mice in our study.
Furthermore, it has been reported that the accumulation
of T cells in inflamed lymph nodes is highly CXCR3
dependent, but not CCR4 dependent [37]. Thus, we spec-
ulated that decreased recruitment of T cells in other or-
gans including inflamed lymph nodes, not only in the
synovium, would be observed in Cxcl10–/– and Cxcr3–/–
mice; however, this hypothesis remains to be elucidated.
Collectively, our study provides data on the functional
roles and molecular mechanisms of CXCL10 signaling in
local and systemic inflammatory processes in RA. A
study from human phase II clinical trials using anti-
CXCL10 monoclonal antibody (MDX-1100) in RA
patients has shown an improved response rate on day 58
[52]. In the present study, reducing the clinical severity
of CAIA was more effective in Cxcr3–/– mice than in
Fig. 6 Reduction of osteoclastogenic cytokine levels in serum and spleen of Cxcl10–/– and Cxcr3–/– mice with CAIA. a, b Serum was collected
from the same WT, Cxcl10–/– (a), and Cxcr3–/– (b) mice as in Fig. 3 on day 12. Serum levels of CXCL10, RANKL, TNFα, IL-6, and CTX were measured
by ELISA. Data represent mean ± SEM. *P < 0.001 by one-way ANOVA followed by Dunnett’s test. c, d Spleens were collected from the same WT,
Cxcl10–/– (c), and Cxcr3–/– (d) mice as in Fig. 3 on day 12. RANKL, TNFα, IL-6, and CXCL10 mRNA levels were analyzed by real-time PCR. Data
represent mean ± SEM of results in five samples (n = 5). *P < 0.001 vs WT mice by unpaired Student’s t test. WT wild-type, CXCL10 C-X-C motif
chemokine 10, Cxcr3 CXC chemokine receptor 3, CAIA collagen antibody-induced arthritis, RANKL receptor activator of nuclear factor kappa-B
ligand, TNFα tumor necrosis factor α, IL-6 interleukin 6, CTX C-terminal telopeptide, ND not detected
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Cxcl10–/– mice (Fig. 3b, c). This might be due to the
presence of other CXCR3 ligands including CXCL9 and
CXCL11. Indeed, CXCL9 has been shown to be in-
creased in the serum of RA patients [16]. In addition,
CAIA-induced elevation of CXCL10 levels was abro-
gated in Cxcr3–/– mice (Fig. 6b, d). Thus, these findings
suggest that CXCR3 would be a more attractive thera-
peutic target for RA than CXCL10.
Conclusions
CXCL10 increased cell migration via CXCR3, not TLR4.
However, both the CXCR3 and TLR4 receptors were re-
quired for CXCL10 to stimulate cytokine production in
CD4+ T cells. The activated calcineurin-dependent NFATc1
pathway was essential for CXCL10-induced RANKL ex-
pression in CD4+ T cells. Arthritic Cxcl10–/– and Cxcr3–/–
mice showed milder bone destruction, serum cytokines,
and cell infiltration into synovium. These results indicate
that CXCL10 may exert pathogenic roles through CXCR3
or TLR4 during arthritis progression.
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